Translational Modeling of Antibacterial Agents
暂无分享,去创建一个
Gauri G. Rao | Neang S. Ly | Brian T. Tsuji | Jürgen B. Bulitta | Alan Forrest | J. Bulitta | A. Forrest | B. Tsuji | G. Rao
[1] M. Kollef,et al. The Epidemiology, Pathogenesis and Treatment of Pseudomonas aeruginosa Infections , 2012, Drugs.
[2] E. Greenberg,et al. A second N-acylhomoserine lactone signal produced by Pseudomonas aeruginosa. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[3] D. Reeves. Advantages and disadvantages of an in-vitro model with two compartments connected by a dialyser: results of experiments with ciprofloxacin. , 1985, The Journal of antimicrobial chemotherapy.
[4] J. Gobburu,et al. Application of modeling and simulation to integrate clinical pharmacology knowledge across a new drug application. , 2002, International journal of clinical pharmacology and therapeutics.
[5] J. Rello,et al. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics. , 2010, The Journal of antimicrobial chemotherapy.
[6] J. Roberts,et al. A method for determining the free (unbound) concentration of ten beta-lactam antibiotics in human plasma using high performance liquid chromatography with ultraviolet detection. , 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[7] G. Drusano,et al. Saturability of Granulocyte Kill of Pseudomonas aeruginosa in a Murine Model of Pneumonia , 2011, Antimicrobial Agents and Chemotherapy.
[8] K. Bush,et al. Affinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and Pseudomonas aeruginosa , 2008, Antimicrobial Agents and Chemotherapy.
[9] Roy Kishony,et al. Drug interactions and the evolution of antibiotic resistance , 2009, Nature Reviews Microbiology.
[10] O. Zak,et al. Animal models as predictors of the safety and efficacy of antibiotics , 1990, European Journal of Clinical Microbiology and Infectious Diseases.
[11] O. Cars,et al. Pharmacodynamic effects of sub-MICs of benzylpenicillin against Streptococcus pyogenes in a newly developed in vitro kinetic model , 1996, Antimicrobial agents and chemotherapy.
[12] S. Srivastava,et al. Pharmacokinetic Mismatch Does Not Lead to Emergence of Isoniazid- or Rifampin-Resistant Mycobacterium tuberculosis but to Better Antimicrobial Effect: a New Paradigm for Antituberculosis Drug Scheduling , 2011, Antimicrobial Agents and Chemotherapy.
[13] A. Lesse,et al. Pharmacodynamics of Vancomycin at Simulated Epithelial Lining Fluid Concentrations against Methicillin-Resistant Staphylococcus aureus (MRSA): Implications for Dosing in MRSA Pneumonia , 2009, Antimicrobial Agents and Chemotherapy.
[14] R. Hancock,et al. Regulation of virulence and antibiotic resistance by two-component regulatory systems in Pseudomonas aeruginosa. , 2009, FEMS microbiology reviews.
[15] M. Bergeron,et al. Inoculum size effect on the MIC of cefoperazone, moxalactam, cefotaxime, cefoxitin and cephalothin for 118 strains of Haemophilus influenzae including 'tolerant' micro-organisms. , 1982, The Journal of antimicrobial chemotherapy.
[16] William J Jusko,et al. Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. , 2009, Drug metabolism and pharmacokinetics.
[17] R. Hancock,et al. Cationic antimicrobial peptides activate a two‐component regulatory system, PmrA‐PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa , 2003, Molecular microbiology.
[18] J. Klastersky,et al. An artificial capillary in vitro kinetic model of antibiotic bactericidal activity. , 1981, The Journal of infectious diseases.
[19] J. Blaser. In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. , 1985, The Journal of antimicrobial chemotherapy.
[20] Y. Yano,et al. Application of logistic growth model to pharmacodynamic analysis of in vitro bactericidal kinetics. , 1998, Journal of pharmaceutical sciences.
[21] P. Seed,et al. Regulation of las and rhl quorum sensing in Pseudomonas aeruginosa , 1997, Journal of bacteriology.
[22] K. Bush. The coming of age of antibiotics: discovery and therapeutic value , 2010, Annals of the New York Academy of Sciences.
[23] Jianguo Zhi,et al. Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due toPseudomonas aeruginosa , 1988, Journal of Pharmacokinetics and Biopharmaceutics.
[24] W. Wehrli,et al. Rifampin: mechanisms of action and resistance. , 1983, Reviews of infectious diseases.
[25] C. Kloft,et al. In vitro pharmacodynamic models to determine the effect of antibacterial drugs. , 2010, The Journal of antimicrobial chemotherapy.
[26] K. Marotti,et al. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions , 1997, Antimicrobial agents and chemotherapy.
[27] M. Zeitlinger,et al. Penetration of Doripenem into Skeletal Muscle and Subcutaneous Adipose Tissue in Healthy Volunteers , 2011, Antimicrobial Agents and Chemotherapy.
[28] J. Li,et al. Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumannii , 2006, Antimicrobial Agents and Chemotherapy.
[29] H. Kitano. Systems Biology: A Brief Overview , 2002, Science.
[30] R. Hancock,et al. Adaptive Resistance to the “Last Hope” Antibiotics Polymyxin B and Colistin in Pseudomonas aeruginosa Is Mediated by the Novel Two-Component Regulatory System ParR-ParS , 2010, Antimicrobial Agents and Chemotherapy.
[31] Neang S. Ly,et al. Development and Qualification of a Pharmacodynamic Model for the Pronounced Inoculum Effect of Ceftazidime against Pseudomonas aeruginosa , 2008, Antimicrobial Agents and Chemotherapy.
[32] B. Iglewski,et al. The chain of command in Pseudomonas quorum sensing. , 1997, Trends in microbiology.
[33] O. Cars,et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. , 2005, The Journal of antimicrobial chemotherapy.
[34] W. Konings,et al. Mechanism of action of the peptide antibiotic nisin in liposomes and cytochrome c oxidase-containing proteoliposomes , 1991, Applied and environmental microbiology.
[35] J. Buynak. β-Lactamase inhibitors: a review of the patent literature (2010 – 2013) , 2013, Expert opinion on therapeutic patents.
[36] D. Orr,et al. Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus. , 1983, The Journal of antimicrobial chemotherapy.
[37] Neang S. Ly,et al. Quantifying Subpopulation Synergy for Antibiotic Combinations via Mechanism-Based Modeling and a Sequential Dosing Design , 2013, Antimicrobial Agents and Chemotherapy.
[38] M. Nishida,et al. New in vitro kinetic model for evaluating bactericidal efficacy of antibiotics , 1980, Antimicrobial Agents and Chemotherapy.
[39] E. Schneider,et al. Comparison of in vivo and in vitro SCE induction. , 1982, Mutation research.
[40] S. Lory,et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen , 2000, Nature.
[41] W R Greco,et al. The search for cytotoxic synergy between anticancer agents: a case of Dorothy and the ruby slippers? , 1996, Journal of the National Cancer Institute.
[42] C. Gomersall,et al. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. , 2001, The Journal of antimicrobial chemotherapy.
[43] Réka Albert,et al. Modeling Systems-Level Regulation of Host Immune Responses , 2007, PLoS Comput. Biol..
[44] Ronald N. Jones,et al. 10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[45] A. MacGowan,et al. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. , 2001, The Journal of antimicrobial chemotherapy.
[46] C. Janeway,et al. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity , 1997, Nature.
[47] Neang S. Ly,et al. Resurgence of Colistin: A Review of Resistance, Toxicity, Pharmacodynamics, and Dosing , 2010, Pharmacotherapy.
[48] S. Akira,et al. Pathogen Recognition and Innate Immunity , 2006, Cell.
[49] Brian T. Tsuji,et al. Front-Loaded Linezolid Regimens Result in Increased Killing and Suppression of the Accessory Gene Regulator System of Staphylococcus aureus , 2012, Antimicrobial Agents and Chemotherapy.
[50] C. Janion. Inducible SOS Response System of DNA Repair and Mutagenesis in Escherichia coli , 2008, International journal of biological sciences.
[51] C. Gyles,et al. Pathogenesis of bacterial infections in animals , 2004 .
[52] J. Bartlett,et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[53] George L. Drusano,et al. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug' , 2004, Nature Reviews Microbiology.
[54] W. Craig,et al. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[55] I. P. Fomina,et al. A dynamic model for in-vitro evaluation of antimicrobial action by simulation of the pharmacokinetic profiles of antibiotics. , 1989, The Journal of antimicrobial chemotherapy.
[56] G. Drusano,et al. Use of Preclinical Data for Selection of a Phase II/III Dose for Evernimicin and Identification of a Preclinical MIC Breakpoint , 2001, Antimicrobial Agents and Chemotherapy.
[57] Wojciech Krzyzanski,et al. Assessment of Drug Interactions Relevant to Pharmacodynamic Indirect Response Models , 2004, Journal of Pharmacokinetics and Pharmacodynamics.
[58] Neang S. Ly,et al. New Dosing Strategies for an Old Antibiotic: Pharmacodynamics of Front-Loaded Regimens of Colistin at Simulated Pharmacokinetics in Patients with Kidney or Liver Disease , 2013, Antimicrobial Agents and Chemotherapy.
[59] S. Akira,et al. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. , 2011, Immunity.
[60] D. Paterson,et al. Clinically Relevant Plasma Concentrations of Colistin in Combination with Imipenem Enhance Pharmacodynamic Activity against Multidrug-Resistant Pseudomonas aeruginosa at Multiple Inocula , 2011, Antimicrobial Agents and Chemotherapy.
[61] R. H. Baltz. Daptomycin: mechanisms of action and resistance, and biosynthetic engineering. , 2009, Current opinion in chemical biology.
[62] M. Bounthavong,et al. Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination , 2013 .
[63] G. Drusano,et al. Impact of Burden on Granulocyte Clearance of Bacteria in a Mouse Thigh Infection Model , 2010, Antimicrobial Agents and Chemotherapy.
[64] G. Drusano,et al. The Combination of Rifampin plus Moxifloxacin Is Synergistic for Suppression of Resistance but Antagonistic for Cell Kill of Mycobacterium tuberculosis as Determined in a Hollow-Fiber Infection Model , 2010, mBio.
[65] J. Blaser,et al. Two compartment kinetic model with multiple artificial capillary units. , 1985, The Journal of antimicrobial chemotherapy.
[66] V. Tamassia,et al. New In Vitro Model to Study the Effect of Antibiotic Concentration and Rate of Elimination on Antibacterial Activity , 1978, Antimicrobial Agents and Chemotherapy.
[67] R. Hancock,et al. PhoP–PhoQ homologues in Pseudomonas aeruginosa regulate expression of the outer‐membrane protein OprH and polymyxin B resistance , 1999, Molecular microbiology.
[68] A. Louie,et al. Impact of Granulocytes on the Antimicrobial Effect of Tedizolid in a Mouse Thigh Infection Model , 2011, Antimicrobial Agents and Chemotherapy.
[69] Robert Leary,et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. , 2003, The Journal of clinical investigation.
[70] S. Keil,et al. Mathematical corrections for bacterial loss in pharmacodynamic in vitro dilution models , 1995, Antimicrobial agents and chemotherapy.
[71] M. Laub,et al. Specificity in two-component signal transduction pathways. , 2007, Annual review of genetics.
[72] Alan Forrest,et al. Novel Pharmacokinetic-Pharmacodynamic Model for Prediction of Outcomes with an Extended-Release Formulation of Ciprofloxacin , 2004, Antimicrobial Agents and Chemotherapy.
[73] A. Vinks,et al. Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion , 1997, Antimicrobial agents and chemotherapy.
[74] Mats O. Karlsson,et al. Semimechanistic Pharmacokinetic/Pharmacodynamic Model for Assessment of Activity of Antibacterial Agents from Time-Kill Curve Experiments , 2006, Antimicrobial Agents and Chemotherapy.
[75] J. Roberts,et al. Protein Binding of β-Lactam Antibiotics in Critically Ill Patients: Can We Successfully Predict Unbound Concentrations? , 2013, Antimicrobial Agents and Chemotherapy.
[76] W. Craig,et al. Animal model pharmacokinetics and pharmacodynamics: a critical review. , 2002, International journal of antimicrobial agents.
[77] Neang S. Ly,et al. Pharmacodynamic Variability beyond That Explained by MICs , 2013, Antimicrobial Agents and Chemotherapy.
[78] Neang S. Ly,et al. Attenuation of Colistin Bactericidal Activity by High Inoculum of Pseudomonas aeruginosa Characterized by a New Mechanism-Based Population Pharmacodynamic Model , 2010, Antimicrobial Agents and Chemotherapy.
[79] F. Tangy,et al. Mechanism of action of aminoglycoside antibiotics. Binding studies of tobramycin and its 6'-N-acetyl derivative to the bacterial ribosome and its subunits. , 1979, European journal of biochemistry.
[80] Yaning Wang,et al. Impact of Pharmacometric Analyses on New Drug Approval and Labelling Decisions , 2011, Clinical pharmacokinetics.
[81] J. Prescott,et al. Pathogenesis of Bacterial Infections in Animals: Gyles/Pathogenesis of Bacterial Infections in Animals , 2010 .
[82] Manuel T. Silva,et al. Neutrophils and macrophages work in concert as inducers and effectors of adaptive immunity against extracellular and intracellular microbial pathogens , 2010, Journal of leukocyte biology.
[83] E. R. Garrett,et al. Kinetics and mechanisms of action of drugs on microorganisms. XI. Effect of erythromycin and its supposed antagonism with lincomycin on the microbial growth of Escherichia coli. , 1970, Journal of pharmaceutical sciences.
[84] J. Korth-Bradley,et al. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. , 2006, The Journal of antimicrobial chemotherapy.
[85] D. Stevens,et al. Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. , 1993, The Journal of infectious diseases.
[86] P. McNamara,et al. Pharmacodynamic Modeling of Ciprofloxacin Resistance in Staphylococcus aureus , 2005, Antimicrobial Agents and Chemotherapy.
[87] W. Hammes,et al. On the Mechanism of Action of Vancomycin: Inhibition of Peptidoglycan Synthesis in Gaffkya homari , 1974, Antimicrobial Agents and Chemotherapy.
[88] C Garnett,et al. Impact of Pharmacometric Reviews on New Drug Approval and Labeling Decisions—a Survey of 31 New Drug Applications Submitted Between 2005 and 2006 , 2007, Clinical pharmacology and therapeutics.
[89] M. Webber,et al. Molecular mechanisms of antibiotic resistance , 2014, Nature Reviews Microbiology.
[90] W. Greco,et al. The search for synergy: a critical review from a response surface perspective. , 1995, Pharmacological reviews.
[91] E. R. Garrett,et al. Kinetics and mechanisms of action of drugs on microorganisms. VII. Quantitative adherence of sulfonamide action on microbial growth to a receptor-site model. , 1967, Journal of pharmaceutical sciences.
[92] T. Cebula,et al. Molecular analysis of mutS expression and mutation in natural isolates of pathogenic Escherichia coli. , 2003, Microbiology.
[93] L. Pan,et al. Plasmid-mediated quinolone resistance – current knowledge and future perspectives , 2013, The Journal of international medical research.
[94] Neang S. Ly,et al. Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies. , 2016, The Journal of antimicrobial chemotherapy.